Form Type: 4

SEC EDGAR Link
Acccession Number:0001070081-19-000059
Date:2019-12-03
Issuer: PTC THERAPEUTICS, INC. (PTCT)
Original Submission Date:

Reporting Person:

PELTZ STUART WALTER
C/O PTC THERAPEUTICS, INC.
100 CORPORATE COURT SOUTH PLAINFIELD, NJ 07080

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-12-03 S 3,482 d $50.00 18,676 indirect
COMMON STOCK 2019-12-03 M 3,900 a $10.85 22,576 indirect
COMMON STOCK 2019-12-03 S 3,900 d $50.00 18,676 indirect
COMMON STOCK 2019-12-03 M 125 a $12.64 18,801 indirect
COMMON STOCK 2019-12-03 S 125 d $50.00 18,676 indirect
COMMON STOCK 2019-12-03 M 559 a $11.23 19,235 indirect
COMMON STOCK 2019-12-03 S 559 d $50.00 18,676 indirect
COMMON STOCK 2019-12-03 M 1,000 a $12.64 19,676 indirect
COMMON STOCK 2019-12-03 S 1,000 d $50.00 18,676 indirect
COMMON STOCK 2019-12-03 M 5,741 a $11.23 24,417 indirect
COMMON STOCK 2019-12-03 S 5,741 d $50.00 18,676 indirect
COMMON STOCK 2019-12-03 M 7,656 a $18.01 26,332 indirect
COMMON STOCK 2019-12-03 S 7,656 d $50.00 18,676 indirect
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 10.85 2019-12-03 deemed execution date M 3,900 (d) 2023-05-15 common stock 3,900 $10.85 0 indirect by spouse
STOCK OPTION (RIGHT TO BUY) 12.64 2019-12-03 deemed execution date M 125 (d) 2026-11-16 common stock 125 $12.64 1,875 indirect by spouse
STOCK OPTION (RIGHT TO BUY) 11.23 2019-12-03 deemed execution date M 559 (d) 2027-01-02 common stock 559 $11.23 12,041 indirect by spouse
STOCK OPTION (RIGHT TO BUY) 12.64 2019-12-03 deemed execution date M 1,000 (d) 2026-11-16 common stock 1,000 $12.64 875 indirect by spouse
STOCK OPTION (RIGHT TO BUY) 11.23 2019-12-03 deemed execution date M 5,741 (d) 2027-01-02 common stock 5,741 $11.23 6,300 indirect by spouse
STOCK OPTION (RIGHT TO BUY) 18.01 2019-12-03 deemed execution date M 7,656 (d) 2028-01-02 common stock 7,656 $18.01 22,969 indirect by spouse
STOCK OPTION (RIGHT TO BUY) 1149.6 deemed execution date 0 ( ) 2020-02-02 common stock 37 $1,149.60 37 indirect by spouse
STOCK OPTION (RIGHT TO BUY) 218.4 deemed execution date 0 ( ) 2022-01-10 common stock 38 $218.40 38 indirect by spouse
STOCK OPTION (RIGHT TO BUY) 490.8 deemed execution date 0 ( ) 2021-04-27 common stock 58 $490.80 58 indirect by spouse
STOCK OPTION (RIGHT TO BUY) 30.86 deemed execution date 0 ( ) 2026-01-03 common stock 11,000 $30.86 11,000 indirect by spouse
STOCK OPTION (RIGHT TO BUY) 51.0 deemed execution date 0 ( ) 2025-01-02 common stock 10,880 $51.00 10,880 indirect by spouse
STOCK OPTION (RIGHT TO BUY) 27.05 deemed execution date 0 ( ) 2024-01-28 common stock 4,900 $27.05 4,900 indirect by spouse
STOCK OPTION (RIGHT TO BUY) 33.02 deemed execution date 0 ( ) 2029-01-21 common stock 26,950 $33.02 26,950 indirect by spouse
Footnotes
IDfootnote
f1 the transactions reported in this form 4 were effected pursuant to a written rule 10b5-1 plan adopted by the reporting person's spouse on march 13, 2019.
f2 currently exercisable.
f3 this option was granted on november 17, 2016 and vests over four years, with 25% of the shares underlying the option vesting on november 17, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on february 17, 2018.
f4 this option was granted on january 3, 2017 and vests over four years, with 25% of the shares underlying the option vesting on january 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on april 3, 2018.
f5 this option was granted on january 3, 2018 and vests over four years, with 25% of the shares underlying the option vesting on january 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on april 3, 2019.
f6 this option was granted on january 4, 2016, and vests over four years, with 25% of the shares underlying the option vesting on january 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on april 4, 2017.
f7 this option was granted on january 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on january 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning april 22, 2020.

Elevate your investments